SWOG clinical trial number
SWOG-9023
Cytogenetic and Flow Cytometric Analysis of Solid Tumors: Renal Cell Carcinoma: A Companion Study to SWOG-8949
Closed
Phase
Published
Abbreviated Title
Cytogenetic and Flow Cytometric Analysis of Solid Tumors: Renal Cell Carcinoma: A Companion Study to SWOG-8949
Activated
07/01/1993
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2002
Cytogenetic and flow cytometric results in advanced renal cell carcinoma: a Southwest Oncology Group study
1997
Comparison of cytogenetic and flow cytometric results of renal cell carcinoma (RCC) performed in the Southwst Oncology Group (SWOG).
1993
Multidrug resistance: clinical relevance in acute leukemia
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase